Lab-grown dopamine cells aim to reboot movement in Parkinson’s patients
Researchers are testing implanted induced pluripotent stem cells engineered to become dopamine-producing neurons in the brains of Parkinson’s patients in a Phase 1 trial. Delivered via MRI-guided surgery into the basal ganglia, the goal is to restore dopamine production, improve motor function, and slow disease progression. The 12-person study (RNDP-001) is monitored for 12–15 months with long-term follow-up planned for up to five years to assess safety (e.g., dyskinesia, infection) and efficacy, and it has FDA fast-track designation.
